ライフサイエンスコーパス: sofosbuvir

1 e at 12 weeks after completion of ledipasvir-sofosbuvir.

2 from phase 2 and 3 studies of ledipasvir and sofosbuvir.

3 eiving 12 weeks of treatment with ledipasvir/sofosbuvir.

4 genetically stable in cell cultures without sofosbuvir.

5 who received at least one dose of ledipasvir-sofosbuvir.

6 ts in HCV genotype 3 that reduce response to sofosbuvir.

7 the highly successful anti-hepatitis C drug sofosbuvir.

8 ther variants, reduces the virus response to sofosbuvir.

9 treatment discontinuations due to ledipasvir-sofosbuvir.

10 aged 3 to <6 years weighing <17 kg received sofosbuvir 150 mg, and patients aged 3 to <6 years weigh

11 nd all patients aged 6 to <12 years received sofosbuvir 200 mg once daily.

12 data from 1788 patients receiving ledipasvir-sofosbuvir (282 for 8 weeks, 910 for 12 weeks, 510 for 2

13 t position 206 reduced the virus response to sofosbuvir 35.77-fold.

14 Fifty-two patients received sofosbuvir 400 mg once daily and weight-based ribavirin

15 CC, non-CC]) to simeprevir 150 mg once daily+sofosbuvir 400 mg once daily for 12 or 8 weeks.

16 received oral simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks.

17 ed the combination of ledipasvir (90 mg) and sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily,

18 Patients self-administered a combined sofosbuvir (400 mg) and velpatasvir (100 mg) tablet once

19 signed 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24 weeks.

20 signed 1:1 to receive ledipasvir (90 mg) and sofosbuvir (400 mg) for 12 or 24 weeks.

21 rticipants were given ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once

22 They received sofosbuvir (400 mg/day) plus daclatasvir (60 mg/day) for

23 s, V at position 150 reduced the response to sofosbuvir 7-fold.

24 n 206, significantly reduced the response to sofosbuvir (8.34-fold reduction); the combinations of V

25 All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-based ribaviri

26 fixed-dose combination tablet of ledipasvir-sofosbuvir (90/400 mg) once daily for 12 weeks.

27 rval [CI], 96.7-98.8%) with daclatasvir plus sofosbuvir, 97.9% (95% CI, 94.8-99.2%) with ledipasvir/s

28 The approval of sofosbuvir, a nucleoside monophosphate prodrug, highligh

29 Among 13 patients exposed to sofosbuvir and an NS5A inhibitor (daclatasvir, ledipasvi

30 tion should be treated with a combination of sofosbuvir and an NS5A inhibitor for 8 weeks.

31 ype 1 infection with treatment failure after sofosbuvir and an NS5A inhibitor.

32 The treatment with FDC of sofosbuvir and daclatasvir achieved high SVR12 rates, eq

33 The combination of sofosbuvir and daclatasvir is a potent, pangenotypic reg

34 With the introduction of generic, low-cost sofosbuvir and daclatasvir, large-scale studies in resou

35 nder the curve and maximum concentration for sofosbuvir and GS-331007 in adolescents were within pred

36 as inhibited by the HCV polymerase inhibitor sofosbuvir and high concentrations of HCV NS5A antiviral

37 R12) with regimens containing ledipasvir and sofosbuvir and identify factors associated with treatmen

38 The pharmacokinetics of sofosbuvir and its metabolite GS-331007 were evaluated b

39 The most commonly used regimen was sofosbuvir and ledipasvir (n = 21).

40 According to the label, sofosbuvir and ledipasvir can be prescribed for 8 weeks

41 lls in 20 HCV patients who achieved SVR with Sofosbuvir and Ledipasvir for 12 weeks and compared with

42 ieve an ultrarapid response were switched to sofosbuvir and ledipasvir for either 8 weeks or 12 weeks

43 fore, we assessed the efficacy and safety of sofosbuvir and ledipasvir in renal transplant patients w

44 We evaluated the effectiveness of sofosbuvir and ledipasvir in treatment-naive and treatme

45 uvir, MK-3682, dasabuvir, or combinations of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir

46 b, or 4 were treated with the combination of sofosbuvir and ledipasvir without ribavirin for 8 or 12

47 Available treatment options included sofosbuvir and ledipasvir/sofosbuvir-based regimens.

48 uvir plus ribavirin, 87.0% in patients given sofosbuvir and pegylated-interferon plus ribavirin, and

49 no significant difference between ledipasvir/sofosbuvir and PrOD regimens), 86.2% (95% CI, 84.6%-87.7

50 Nineteen participants commenced sofosbuvir and ribavirin (89% male, 74% with human immun

51 of this study was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with

52 We evaluated the all-oral combination of sofosbuvir and ribavirin in adolescents aged 12-17 with

53 Ledipasvir-sofosbuvir and ribavirin provided high rates of SVR12 fo

54 Sofosbuvir and ribavirin was safe and highly effective i

55 Six weeks of sofosbuvir and ribavirin was safe and well tolerated, bu

56 hose with genotype 2 infection (treated with sofosbuvir and ribavirin), 74.8% (95% CI, 72.2%-77.3%) o

57 notype 3 infection who had been treated with sofosbuvir and ribavirin, with or without pegylated inte

58 ed with a reduced response to treatment with sofosbuvir and ribavirin, with or without pegylated inte

59 ave high rates of response to treatment with sofosbuvir and ribavirin.

60 of interest and tested their sensitivity to sofosbuvir and ribavirin.

61 gated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors i

62 and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in

63 In patients given sofosbuvir and velpatasvir for 12 weeks (n=90), clinical

64 combinations of sofosbuvir and ledipasvir or sofosbuvir and velpatasvir had decreased efficacy agains

65 Treatment with combined sofosbuvir and velpatasvir has resulted in high sustaine

66 ed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A

67 cirrhosis given a fixed-dose combination of sofosbuvir and velpatasvir with and without ribavirin.

68 lated decompensated cirrhosis who were given sofosbuvir and velpatasvir without ribavirin.

69 re, during, and after antiviral therapy with sofosbuvir and velpatasvir, we found that intrahepatic M

70 ic response after 12 weeks of treatment with sofosbuvir and velpatasvir.

71 , 97.9% (95% CI, 94.8-99.2%) with ledipasvir/sofosbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuv

72 ing, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR

73 orms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C v

74 Regimens containing ledipasvir and sofosbuvir are highly effective for a broad spectrum of

75 ed weight-based doses of combined ledipasvir-sofosbuvir as granules (33.75 mg/150 mg for weights <17

76 riority in SVR12 was assessed for simeprevir+sofosbuvir at 12 and 8 weeks versus a composite historic

77 Sofosbuvir at 400 mg and daclatasvir at 60 mg were cofor

78 kidney transplant recipients with ledipasvir-sofosbuvir at our 2 centers.

79 Sofosbuvir-based antiviral therapy for HCV recurrence af

80 We conclude that sofosbuvir-based DAA therapy is safe and highly effectiv

81 ve and retrospective, open-label study using sofosbuvir-based DAA therapy to treat HIV/HCV-coinfected

82 Here, we asked whether HCV-elimination by sofosbuvir-based direct-acting antivirals (DAAs) and add

83 Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other D

84 t options included sofosbuvir and ledipasvir/sofosbuvir-based regimens.

85 CV genotype 3 responds slightly less well to sofosbuvir-based therapies than other genotypes.

86 ent with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir.

87 Sofosbuvir-Containing Regimens Without Interferon for Tr

88 The sofosbuvir-containing regimens without interferon for tr

89 Among patients failed by sofosbuvir-containing regimens, L159F was enriched in pa

90 In patients treated with sofosbuvir-containing regimens, the A150V variant was as

91 genotype 1 infection; the dose of ledipasvir-sofosbuvir currently used in adults was well tolerated i

92 ived interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks

93 vir; and two [33%] of six patients receiving sofosbuvir, daclatasvir, and asunaprevir) and headache (

94 sofosbuvir, daclatasvir, and simeprevir; or sofosbuvir, daclatasvir, and asunaprevir) until six pati

95 sofosbuvir plus daclatasvir for 24 weeks or sofosbuvir, daclatasvir, and ribavirin for 12 weeks are

96 aprevir; one [17%] of six patients receiving sofosbuvir, daclatasvir, and simeprevir; and two [33%] o

97 ps (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, daclatasvir, and simeprevir; or sofosbuvir,

98 d the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in di

99 r/simeprevir would be expected in 31.4%, for sofosbuvir/daclatasvir in 36.8%, and for sofosbuvir/ledi

100 h age group confirmed the appropriateness of sofosbuvir doses.

101 ed efficacy against infection with the DBN3a sofosbuvir escape variant.

102 These findings indicate that sofosbuvir escape variants could compromise the effectiv

103 Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolerated and see

104 Conclusion: Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks was well-tolerated and see

105 acy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

106 -naive and -experienced patients, ledipasvir-sofosbuvir for 12 weeks is highly effective for the trea

107 Add-on of sofosbuvir for 6 months was associated with HEV RNA beco

108 eved by 96% of patients receiving ledipasvir-sofosbuvir for 8 weeks (95% CI, 93%-98%), 97% receiving

109 efficacy and safety of 6 weeks of ledipasvir-sofosbuvir for acute genotype 1 or 4 HCV in HIV-1-coinfe

110 l trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men with HIV infe

111 ablish the safety and efficacy of ledipasvir-sofosbuvir for chronic HCV genotype 1 or 4 infection in

112 with a fixed-dose combination of ledipasvir-sofosbuvir for patients with acute genotype 1 or 4 HCV i

113 safety and efficacy of 8 weeks of ledipasvir/sofosbuvir for the treatment of acute HCV infections in

114 efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor

115 Sofosbuvir has shown antiviral activity against HEV in v

116 simeprevir (HCV NS3/4A protease inhibitor) + sofosbuvir (HCV nucleotide analogue NS5B polymerase inhi

117 -fusion assay to assess viral sensitivity to sofosbuvir in 14 HCV genotype 3 samples.

118 aluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV genotype 1 in

119 aluate the safety and efficacy of ledipasvir/sofosbuvir in black patients using data from the three o

120 olecular basis supporting the current use of Sofosbuvir in combination with other drugs in COVID-19 c

121 a small effect in patients given ledipasvir/sofosbuvir in combination with ribavirin for 12 weeks.

122 y and safety of 12 and 8 weeks of simeprevir+sofosbuvir in HCV GT1-infected treatment-naive and treat

123 icacy and safety of 12 weeks of simeprevir + sofosbuvir in HCV GT1-infected treatment-naive or treatm

124 luated the safety and efficacy of ledipasvir-sofosbuvir in HCV-infected children aged 3 to <6 years.

125 feron- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients with chronic

126 feron- and ribavirin-free regimen ledipasvir-sofosbuvir in kidney transplant recipients with chronic

127 aluate the safety and efficacy of ledipasvir-sofosbuvir in Rwandan adults with chronic HCV infection

128 42% of patients) with a reduced response to sofosbuvir in virus replication assays.

129 ully provided at least month-long release of sofosbuvir in vivo.

130 ted three DAAs (simeprevir, daclatasvir, and sofosbuvir) in combination with anti-miR-122 treatment a

131 combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.

132 Sofosbuvir is a frequently used pan-genotype inhibitor o

133 Ledipasvir-sofosbuvir is effective at eradicating hepatitis C virus

134 An 8-week regimen of ledipasvir/sofosbuvir is effective for eligible patients with HCV g

135 a suggest that the clinical effectiveness of sofosbuvir is largely a function of being intractable to

136 ons included sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDV/SOF) based regimens.

137 Eight weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hep

138 The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care setting

139 ombitasvir, dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality.

140 tudy, black patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less likely to a

141 -inhibitor (GS-9451) and after 12 weeks with sofosbuvir + ledipasvir.

142 ed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-i

143 fatigue (one [17%] of six patients receiving sofosbuvir, ledipasvir, and asunaprevir; one [17%] of si

144 er program to one of three treatment groups (sofosbuvir, ledipasvir, and asunaprevir; sofosbuvir, dac

145 e (tau) and maximum concentration values for sofosbuvir, ledipasvir, and GS-331007 were within the pr

146 okinetic evaluation of the concentrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS

147 luding tenofovir alafenamide, emtricitabine, sofosbuvir, ledipasvir, and velpatasvir were inactive at

148 eal-world practice setting, daclatasvir plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpat

149 regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombit

150 ients underwent antiviral therapy (AVT) with sofosbuvir/ledipasvir and chemotherapy (14 rituximab plu

151 for sofosbuvir/daclatasvir in 36.8%, and for sofosbuvir/ledipasvir in 40.2%.

152 We compared using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprev

153 mbitasvir, paritaprevir/ritonavir/dasabuvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respe

154 Sofosbuvir may have some antiviral activity against HEV

155 ntrations of sofosbuvir, ledipasvir, and the sofosbuvir metabolite GS-331007.

156 Sofosbuvir, MK-3682, dasabuvir, or combinations of sofos

157 Short 8-week ledipasvir/sofosbuvir monotherapy regimens should perhaps be avoide

158 1-infected patients treated with ledipasvir/sofosbuvir monotherapy, black patients had significantly

159 tasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57)

160 received 12 to 24 weeks of daclatasvir plus sofosbuvir (n = 767), ledipasvir/sofosbuvir (n = 197), o

161 ION-4, and ALLY-2 that evaluated simeprevir; sofosbuvir; ombitasvir, paritaprevir/ritonavir/dasabuvir

162 nation tablet of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks.

163 All patients received ledipasvir-sofosbuvir once daily for 6 weeks.

164 (90 mg) and sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily, with or without ribavirin twice

165 terferon or pegylated interferon, ribavirin, sofosbuvir, or a combination of these medications.

166 osbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ombitasvir/ritonavir/dasabuv

167 tablet of 90 mg of ledipasvir and 400 mg of sofosbuvir orally once-daily for 12 weeks.

168 re polymorphisms that reduced sensitivity to sofosbuvir our cell system.

169 those who are treatment experienced, whereas sofosbuvir, pegylated interferon, and ribavirin for 12 w

170 s standard of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon/ribavirin, was included

171 fection who received previous treatment with sofosbuvir plus an NS5A inhibitor, 16 weeks treatment wi

172 (HCV) infection with treatment failure after sofosbuvir plus an NS5A inhibitor.

173 fection who received previous treatment with sofosbuvir plus an NS5A inhibitor.

174 ribavirin for 24 weeks, 4 patients received sofosbuvir plus daclatasvir for 12 weeks, and 2 patients

175 For genotype 3 infections, sofosbuvir plus daclatasvir for 24 weeks or sofosbuvir,

176 VID-19 clinical trials with EPCLUSA and with Sofosbuvir plus Daclatasvir have been initiated in sever

177 l, interferon- and ribavirin-free regimen of sofosbuvir plus daclatasvir in patients with HCV-associa

178 pe 1 infections, sofosbuvir plus ledipasvir, sofosbuvir plus daclatasvir, or ombitasvir, paritaprevir

179 vir plus pegylated interferon and ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plus ribavirin

180 Ideally, for genotype 1 infections, sofosbuvir plus ledipasvir, sofosbuvir plus daclatasvir,

181 terferon plus ribavirin has been replaced by sofosbuvir plus pegylated interferon and ribavirin, and

182 For genotype 6, sofosbuvir plus pegylated interferon and ribavirin, sofo

183 erent duration) and 311 receiving ledipasvir-sofosbuvir plus ribavirin (212 for 12 weeks and 81 for 2

184 ron or pegylated interferon +/- ribavirin or sofosbuvir plus ribavirin +/- pegylated interferon thera

185 nd ribavirin, sofosbuvir plus ledipasvir, or sofosbuvir plus ribavirin for 12 weeks are all suitable.

186 udy, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged

187 sessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immuno

188 eated with DAA therapy (21 patients received sofosbuvir plus ribavirin for 24 weeks, 4 patients recei

189 d for the safety and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV

190 tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HC

191 Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly

192 ted interferon with or without ribavirin, or sofosbuvir plus ribavirin with or without pegylated inte

193 plus ribavirin, and 70.6% of patients given sofosbuvir plus ribavirin), and 89.6% (95% CI 82.8%-93.9

194 nfection (77.9% in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients given sofos

195 tasvir for 12 weeks, and 2 patients received sofosbuvir plus simeprevir for 12 weeks) in Paris, Franc

196 analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor v

197 Seven patients (2%) discontinued ledipasvir-sofosbuvir prematurely due to adverse events.

198 with genotype 3 HCV, 12 weeks of ledipasvir-sofosbuvir provided a high level of SVR in those without

199 antiviral in 53.4%, PegIFN-RBV in 34.5%, and sofosbuvir/RBV in 12.2%.

200 uvir; sofosbuvir/ledipasvir; and daclatasvir/sofosbuvir, respectively, to the Canadian Coinfection Co

201 uated a fixed-dose combination of ledipasvir/sofosbuvir +/- ribavirin administered for 8, 12, or 24 w

202 c response (SVR12), and safety of ledipasvir/sofosbuvir +/- ribavirin.

203 GT) 1-infected patients receiving simeprevir+sofosbuvir+/-ribavirin for 12 or 24 weeks.

204 Sofosbuvir-ribavirin for 12 weeks for the treatment of a

205 Sofosbuvir/ribavirin had the lowest risk to cause a pote

206 antiviral treatment with regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/sofosbuv

207 The previous standard of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon

208 Significant DDIs for sofosbuvir/simeprevir would be expected in 31.4%, for so

209 Sofosbuvir (SOF) + daclatasvir +/- ribavirin (RBV) was u

210 ir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4-12 weeks.

211 tions were developed: Dactavira, composed of sofosbuvir (SOF) 400 mg/daclatisvir (DCV) 60 mg/epigallo

212 ug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype 1b replicon to deter

213 Available treatment options included sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDV/SOF) bas

214 virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks.

215 oss 11 phase 3 clinical trials of ledipasvir-sofosbuvir (SOF) and SOF, only 12 of 3004 patients had d

216 efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HCV genotype-1 (GT-1) p

217 Ledipasvir (LDV)/sofosbuvir (SOF) has demonstrated high efficacy, safety,

218 ety, and tolerability of regimens containing sofosbuvir (SOF) in the treatment of hepatitis C virus (

219 the safety and efficacy of ledipasvir (LDV)-sofosbuvir (SOF) in treating HCV genotype-4 infected pat

220 (BOC) or telaprevir (TEL) for 48 weeks, and sofosbuvir (SOF) plus daclastavir (DCV) or simeprevir (S

221 Sofosbuvir (SOF)-based regimens may not be optimal among

222 mens posttransplant, particularly the use of sofosbuvir (SOF)/ledipasvir (LDV) without RBV in this pa

223 and 8% GT1 no subtype) and were treated with sofosbuvir (SOF)/ledipasvir +/- ribavirin (85%) followed

224 Treatment regimens used were: Sofosbuvir (SOF)/ribavirin (RBV)/pegylated interferon (P

225 A (NS5A) inhibitors should be retreated with sofosbuvir (SOF; NS5B inhibitor) combined with simeprevi

226 exposure in adults treated in phase 2 and 3 sofosbuvir studies, the area under the curve and maximum

227 We report here that Sofosbuvir terminated RNA resists removal by the exonucl

228 ation of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/

229 e either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the prot

230 uired adjustment during and after ledipasvir-sofosbuvir therapy but antiretroviral regimens did not.

231 l effects on patient responses to ledipasvir/sofosbuvir therapy.

232 ators have since demonstrated the ability of Sofosbuvir to inhibit SARS-CoV-2 replication in lung and

233 to search for virus factors associated with sofosbuvir treatment failure.

234 We subsequently demonstrated that Sofosbuvir triphosphate is incorporated by the relativel

235 Four weeks of sofosbuvir, velpatasvir, and GS-9857 produced an SVR12 i

236 r-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks.

237 All patients received sofosbuvir-velpatasvir (400 mg/100 mg fixed-dose combina

238 cy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjus

239 with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at w

240 phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with gen

241 ta from other phase 3 studies, single-tablet sofosbuvir-velpatasvir for 12 weeks is an efficacious an

242 Sofosbuvir-velpatasvir for 12 weeks was safe and provide

243 -voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens

244 uvir-velpatasvir-voxilaprevir for 8 weeks or sofosbuvir-velpatasvir for 12 weeks.

245 ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenor

246 All patients received sofosbuvir-velpatasvir once daily for 12 weeks.

247 el trial, we found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effec

248 direct-acting antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was w

249 s, none of which was judged to be related to sofosbuvir-velpatasvir treatment.

250 uvir-velpatasvir-voxilaprevir to 12 weeks of sofosbuvir-velpatasvir using a noninferiority margin of

251 Sofosbuvir-velpatasvir, a pangenotypic direct-acting ant

252 n to establish noninferiority to 12 weeks of sofosbuvir-velpatasvir, which produced an SVR in 98% of

253 randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or so

254 confidence interval [CI], 86-100) receiving sofosbuvir-velpatasvir-voxilaprevir alone and 24 of 25 (

255 The most commonly reported AEs with sofosbuvir-velpatasvir-voxilaprevir alone were diarrhea

256 POLARIS-4, the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbu

257 agent were assigned randomly to groups given sofosbuvir-velpatasvir-voxilaprevir for 8 weeks or sofos

258 ith HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noni

259 CV genotype 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

260 enotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group.

261 alone were diarrhea and bronchitis; and with sofosbuvir-velpatasvir-voxilaprevir plus RBV were fatigu

262 Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks p

263 None of the patients discontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of a

264 ned to test the noninferiority of 8 weeks of sofosbuvir-velpatasvir-voxilaprevir to 12 weeks of sofos

265 A fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir was well tolerated a

266 ment with a fixed-dose combination tablet of sofosbuvir-velpatasvir-voxilaprevir with or without riba

267 ypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).

268 of sustained virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0%

269 V genotype 1a infection receiving 8 weeks of sofosbuvir-velpatasvir-voxilaprevir.

270 3%-97%) of patients had an SVR to 8 weeks of sofosbuvir-velpatasvir-voxilaprevir; this did not meet t

271 sbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir.

272 = 767), ledipasvir/sofosbuvir (n = 197), or sofosbuvir/velpatasvir (n = 57), with or without ribavir

273 Participants received sofosbuvir/velpatasvir (once daily; SIMPLIFY) or paritap

274 Participants received sofosbuvir/velpatasvir (once-daily; SIMPLIFY) or paritap

275 Enrolled in 2016-2017, participants received sofosbuvir/velpatasvir (SIMPLIFY) or paritaprevir/ritona

276 plus sofosbuvir, ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir achieved high SVR rates with good

277 c male with genotype 3, who was treated with sofosbuvir/velpatasvir for 6 weeks.

278 ing the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection,

279 t the FDA-approved hepatitis C drug EPCLUSA (Sofosbuvir/Velpatasvir) might inhibit SARS-CoV-2.

280 osbuvir, and 96.5% (95% CI, 88.1-99.0%) with sofosbuvir/velpatasvir.

281 Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosev

282 clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) achiev

283 Ledipasvir-sofosbuvir was highly effective at treating adolescents

284 ir, velpatasvir, pibrentasvir, elbasvir, and sofosbuvir was measured using the S52 DeltaN gt3a replic

285 A once-daily dosage of ledipasvir/sofosbuvir was similarly effective in black and non-blac

286 econd cohort receiving 8 weeks of ledipasvir-sofosbuvir was to be enrolled.

287 Conclusion: Ledipasvir-sofosbuvir was well tolerated and highly effective in ch

288 Ledipasvir-sofosbuvir was well tolerated.

289 has a high genetic barrier to resistance for sofosbuvir, whereas resistance to this DAA can be induce

290 alogs, such as the prodrugs mericitabine and sofosbuvir, which get metabolized to 2'-fluoro-2'C-methy

291 Patients received treatment with ledipasvir-sofosbuvir, which was provided on site, according to U.S

292 gle patient receiving 12 weeks of ledipasvir-sofosbuvir who did not reach SVR12 did not complete trea

293 ing coadministration of the HCV-NS5B prodrug sofosbuvir with amiodarone was recently reported.

294 Sofosbuvir with ledipasvir and sofosbuvir with ribavirin

295 We examined the effectiveness of ledipasvir/sofosbuvir with or without ribavirin (LDV/SOF +/- RBV) a

296 fficacy of 8, 12, and 24 weeks of ledipasvir/sofosbuvir with or without ribavirin for the treatment o

297 Sofosbuvir with ledipasvir and sofosbuvir with ribavirin have received regulatory appro

298 type 3a variants with reduced sensitivity to sofosbuvir, with increased fitness and with cross-resist

299 esponse to the combination of ledipasvir and sofosbuvir, with or without ribavirin, in patients with

300 reated with a chronic HCV regimen containing sofosbuvir without an NS5A inhibitor.

301 been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.